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S U M M A R Y
Background: Knowledge about risk or protective factors for post-treatment outcomes in Cutaneous
Lishmaniosis are rare, especially in endemic areas such as Iran. The present study aimed to evaluate the
association between the outcome of infection, clinical manifestation, and treatment with adverse post-
treatment outcomes in Cutaneous Lishmaniosis patients.
Methods: This was a cross sectional study based on recently collected data of 9077 Cutaneous
Lishmaniosis patients (4585 female and 4492 male) from March 2003 to March 2011 in the Bam area,
Iran. Multivariable multinomial logistic regression was applied to assess the effect of outcome of
infection, clinical manifestation and treatment on relapse, treatment after interruption, treatment
failure and clinical resistance.
Results: Head lesions were strongest risk factor for relapse (Odds Ratio, OR=4.21; CI 95%: 3.56-4.98),
treatment after interruption (2.00; 1.70-2.35), treatment failure (6.61; 5.17-8.45) and clinical resistance
(2.62; 2.00-3.44). Family occurrence (yes vs. no), intra lesion therapy method, treatment duration (>3 v.
 3 week) and source of detection by Surveillance (active vs. passive), were the most protective factors
for relapse (OR=0.58; CI 95%: 0.46-0.74), treatment after interruption (0.36; 0.31-0.42) treatment failure
(0.24; 0.20-0.29) and clinical resistance (0.24; 0.09-0.67).
Conclusion: Head lesions and treatment variables (e.g. therapy method and duration) could predict the
occurrence of adverse post-term outcomes of Cutaneous Lishmaniosis. Further longitudinal studies have
to clarify cause and effect relationships.
 2015 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-SA license (http://creativecommons.org/licenses/by-
nc-sa/4.0/).
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
Cutaneous leishmaniasis (CL) is the most common form of the
leishmaniosis.1 It is estimated that the majority of CL cases is
restricted to some tropical and sub-tropical countries, including
Iran.2 Zoonotic Cutaneous Leishmanias (ZCL) and Anthroponotic
Cutaneous Leishmaniasis (ACL) are occurring in different parts of* Corresponding author: Department of Public Health, School of Nursing and
Midwifery, Maragheh University of Medical Sciences, Maragheh, Iran.
E-mail addresses: S-saﬁri@razi.tums.ac.ir, Saeidsaﬁri@gmail.com (S. Saﬁri).
http://dx.doi.org/10.1016/j.ijid.2015.03.001
1201-9712/ 2015 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-sa/4.0/).Iran, ZCL in central,3 north, north-east,4 ad south-west,5 while
ACL is endemic in large cities including Tehran, Shiraz, Mashhad,
Kerman and small cities like Bam.6 The Kerman province,
especially the city of Bam, was one of the known old focal
points of ACL in Iran.7 There is clear evidence that leishmania
tropica species is the causative parasite of ACL in urban areas that
is transmitted by the bite of the infected sand-ﬂy (Phelebotomus
sergenti). After the 2003 earthquake in the Bam area, the
prevalence of CL signiﬁcantly increased.8 CL usually produces
ulcers on the exposed parts of the body, such as the face, arms
and legs. These lesions may persist for a long time (6-15
months).9ciety for Infectious Diseases. This is an open access article under the CC BY-NC-SA
Figure 1. The proportion of cutaneous leishmaniosis patients by gender (2003-
2011).
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systemic and nonpharmacological treatments, have been intro-
duced, such as paromomycin ointments, thermotherapy, intrale-
sional pentavalent antimonials and cryotherapy; systemic
treatment consists of pentavalent antimonial salts at a daily dose
of 20/mg/kg Sb5+ of pentavalent antimony.10 In Iran, speciﬁc
treatment for cutaneous leishmaniosis is meglumine antimoniate
compound.11
Due to a large number of lesions and permanent scars,
prolonged duration of treatment (several months) is required in
some cases.12 Unfortunately, there are unwanted side effect
according to type of treatment, e.g. pain at the injection site in the
case of interlesional or cardiac and pancreatic toxicity, toxicity-
related mortality in systemic administration, which may be the
reason for non-adherence and non-compliance.9 Subsequently,
studies have shown that as a result, clinical resistance,13 failure14
and consequently disease relapse can occur.15,16 Not only does the
occurrence of relapse and/or treatment failure depend on the
quality of the treatment program, but also the clinical manifesta-
tion of CL may be important.
It should be emphasized that in CL the epidemiologic
relationship between the vector and the human reservoir host
still remain a major challenge. Therefore effective control is not a
realistic goal.1 Nevertheless, reducing the burden of disease by
focusing on the outcomes of infection, clinical manifestation and
treatment can be achieved. However, there is very little evidence
regarding the characteristics of CL patients, particularly in Iran.
Hence, the objectives of the present study were to describe the post
event pattern in CL and to identify determinant risk factors of
adverse outcomes following treatment in south eastern Iran.
2. Materials and Methods
This cross sectional study using pre-existing data from
epidemiologic surveillance systems was conducted from March
2003 to March 2011 in the Kerman province including Bam and
Normashir. 9,077 individuals infected by CL caused by L.tropica
were included in the study. Deﬁnitive cases were conﬁrmed
microscopically by smear or culture from cutaneous lesions.11
To achieve the study objective, these variables were included:
demographic variables (age, sex and nationality) and outcome of
infection, clinical manifestation and treatment including source of
detection of cases (passive or active surveillance), previous scar,
family occurrence, scar covering, comorbidity, therapy duration,
therapy method (intramuscular, local and cryotherapy), body
region involved, scar duration and number of healed lesions. We
classiﬁed the participants into ﬁve case types: a) patients
presenting with active lesion(s) and receiving CL treatment for
the ﬁrst time classiﬁed as new case, b) patients who have been
declared cured of CL in the past by a physician, after one full course
of systemic or local treatment, and returned because of the
reactivation of apparently cured lesion(s) classiﬁed as Relapse, c)
patients who interrupt systemic and local treatment for 10 and
7 days or more, and return to the health service with active lesion,
classiﬁed as treatment after interruption, d) patients who had active
lesion after 4 to 6 months despite complete systemic or local
treatment, classiﬁed as treatment failure, e) patients with relapse or
treatment failure who had active lesion 6 weeks after completing
at least 2 rounds of systemic treatment, classiﬁed as clinical
resistance.17
Distribution of continuous and ordinal variables were assessed
by Histogram plot and Kolmogorov-Smirnov test. According to
normality of data, the Kruskal Wallis H test was used to compare
outcome of infection, clinical manifestation, and treatment among
case types. In addition, the Chi-squared test was used to assess
the association between categorical variables. Multivariablemultinomial logistic regression (adjusted by age, sex and national-
ity) by new cases as a baseline comparison group was used to model
case types as a nominal dependent variable and infection, clinical
manifestation and treatment as independent variable. Odds ratios
(OR) with 95% conﬁdence intervals (CI 95%) were calculated. To
avoid over-parameterization, we excluded some variables because
of low sample sizes: e.g. back and abdomen categories. If there
are more parameters to estimate than observations in the dataset,
then the model is over-parameterized and there is not enough
information to yield valid parameter estimates.
A multivariable multinomial logistic regression model includ-
ing all explanatory variables was constructed to calculate the
probability of each adverse post-term treatment outcomes to
assess the discriminant power of all explanatory variables assessed
by the Receiver Operating Characteristic curve (ROC curve). In a
ROC curve, the true positive rate (Sensitivity) is plotted as a
function of the false positive rate (100-Speciﬁcity) for different cut-
off points of a parameter. Area under the Curve (AUC) measures
discrimination, i.e, the ability of the test to correctly diagnosis each
post-treatment outcomes. Statistical analyses were conducted
using Stata software, version 11 (Stata Corp, College Station, TX,
USA). The level of statistical signiﬁcance for all tests was p  0.05.
3. Results
Median (IQR) age was 2128 years (range 1 to 110). The cases
detected by passive surveillance in female and male subjects was
94.8 and 95%, respectively. The proportion (%) of new, relapse,
treatment after interruption, treatment after failure and chronic
cases in CL patients was 72, 9, 10, 5 and 4, respectively. Age-sex
distribution of the outcomes showed that the proportion of
adverse post-treatment outcomes for male was higher than for
female subjects, except for clinical resistance. Most new reported
cases and relapses were aged under 10 years and between 20 and
40 years, as shown in Figures 1 and 2. A cross tabulation outcome of
infection, clinical manifestation and treatment of CL patients by
case type in detail is presented in Table 1.
Table 2 presents the adjusted prevalence odds ratios (POR) for
all study variables by adverse outcomes after treatment. Multi-
variable multinomial logistic regression after adjusting age, sex
and nationality showed that the occurrence of scar on head (face,
ear and neck) had the strongest effect size on relapse, treatment
after interruption, treatment failure and clinical resistance cases
(OR= 4.21, 2, 6.61 and 2.62 respectively, p 0.001). In the case of
compared intramuscular (IM) injection, as result of intra leshional
Figure 2. The proportion of cutaneous leishmaniosis patients by age group (2003-
2011).
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decreased (OR=0.76, 0.36, 0.24 and 0.42 respectively. p0.01)
The ROC analysis for discrimination power of all explanatory
variables showed that the area under the curve (AUC) for
treatment failure (0.72) was larger than other post-treatment
outcomes (Figure 3).Table 1
Outcome of infection, clinical manifestation and treatment of Cutaneous Leishmaniasis
Variables 
New (n=6548) Relapse n(827) 
Age 22 (26) 12 (26) 
Sex
Female 3370 (51.5) 395 (47.8) 
Male 3178 (48.5) 432 (52.2) 
Nationality
Non-Iranian 149 (2.3) 9 (1.1) 
Iranian 6399 (97.7) 818 (98.9) 
Surveillance
Passive 6218 (95) 754 (91.2) 
Active 330 (5) 73 (8.8) 
Previous scar
No 6261 (95.6) 718 (86.8) 
Yes 287 (4.4) 109 (13.2) 
Family occurrence
No 5544 (84.7) 743 (89.8) 
Yes 1004 (15.3) 84 (10.2) 
Comorbidity
No 6030 (92.1) 766 (92.6) 
Yes 518 (7.9) 61 (7.4) 
Therapy duration
3 1414 (21.6) 211 (25.5) 
>3 5134 (78.4) 616 (74.5) 
Therapy method
Intramuscular (glucantime 20 mg/kg
per day for 14 days)
1410 (21.5) 212 (25.6) 
Intra lesional (glucantime; 20 mg/kg
per day for 10 to 20 days)
4942 (75.5) 578 (69.9) 
Cryotherapy with liquid nitrogen, once
per week for 6 weeks)
196 (3) 37 (4.5) 
Body region involved
Hand 3108 (47.5) 234 (28.3) 
Leg 761 (11.6) 43 (5.2) 
Head (face, ear & neck) 1493 (22.8) 474 (57.3) 
Back 54 (0.8) 3 (0.4) 
Abdomen 30 (0.5) 1 (0.1) 
Multi region involved 1102 (16.8) 72 (8.7) 
Duration of scar incidence 8 (12) 8 (12) 
Number of lesion 1 (1) 2 (2) 
§ Categorical variables shown as n (%) with p-value according to x2, Continuous variab
* p.value 0.054. Discussion
It is obvious that the proportion of adverse post- treatment
outcomes in CL patients is notable. That means, approximately
one-third of the treatments lead to relapse, treatment after
interruption, treatment failure and clinical resistance. Our results
also show that risk of adverse post-treatment outcomes are
associated with each of the assessed explanatory variables
(Outcome of infection, clinical manifestation and treatment),
although strength of associations was quite different. Head lesions
were more modest to strongly signiﬁcant associated with all
outcomes, also therapy duration of more than 3 weeks showed a
signiﬁcant relationship to all dependant variables.
In the present study the most lesions were localized on the
upper extremities in both sexes. Adverse post treatment outcomes
were observed in all age groups. 5 to 9 year olds had the highest
relapse rate, while 30 to 39 years olds showed the lowest
proportions. Gurel et al. found that the highest rate of new cases
occurred in 5 to 9 year group and they pointed out, that as a result
of acquired immunity by increasing age, the occurrence of CL
infection declines.15 However our results show that most of the
new cases have been reported in 20 to 40 year old participants.
Some of these cases could be attributed to the migration of non-
immune workforce and laborers into the Bam area after the
earthquake of 2003. Also, our results indicate disease development
and adverse post-treatment outcomes are a common phenomenon patients by case type (n=9077)
Case type
Treatment after
interruption n(922)
Treatment
failure n(474)
Clinical resistance
n(306)
p-value
20 (29) 12 (25) 20 (32) <0.001
430 (46.6) 228 (48.1) 162 (52.9)
492 (53.4) 246 (51.9) 144 (47.1) 0.016
14 (1.5) 18 (3.8) 6 (2)
908 (98.5) 456 (96.2) 300 (98) 0.012
872 (94.6) 466 (98.3) 302 (98.7)
50 (5.4) 8 (1.7) 4 (1.3) <0.001
865 (93.8) 446 (94.1) 292 (95.4)
57 (6.2) 28 (5.9) 14 (4.6) <0.001
771 (83.6) 423 (89.2) 269 (87.9)
151 (16.4) 51 (10.8) 37 (12.1) <0.001
841 (91.2) 445 (93.9) 283 (92.5)
81 (8.8) 29 (6.1) 23 (7.5) 0.49
390 (42.3) 249 (52.5) 118 (38.6)
532 (57.7) 225 (47.5) 188 (61.4) <0.001
388 (42.1) 247 (52.1) 117 (38.2)
494 (53.6) 216 (45.6) 179 (58.5) <0.001
40 (4.3) 11 (2.3) 10 (3.3)
351 (38.1) 90 (19) 99 (32.4)
84 (9.1) 19 (4) 24 (7.8)
338 (36.7) 286 (60.3) 125 (40.8) <0.001
5 (0.5) 1 (0.2) 0
6 (0.7) 1 (0.2) 0
138 (15) 77 (16.2) 58 (19)
32 (28) 28 (28) 20 (28) <0.001
1(1) 1(1) 1(1) <0.001
les shown as (Median, IQR) z with p-value according to Kruskal Wallis H test
Table 2
Odds ratios (ORs) and 95% conﬁdence intervals (CIs) of explanatory variable among case types
Case type, OR* (95% CI), new case as reference
Variables Relapse Treatment after
interruption
Treatment failure Clinical resistance
Source of detection (Surveillance)
(active vs. passive)
1.83 (1.40-2.38) y 1.08 (0.8-1.47) 0.32 (0.15-0.65) z 0.24 (0.09-0.67) z
Previous scar (yes vs. no) 3.37 (2.66-4.27) y 1.44 (1.08-1.94) § 1.40 (0.93-2.09) 1.04 (0.6-1.81)
Family occurrence (yes vs. no) 0.58 (0.46-0.74) y 1.08 (0.89-1.30) 0.59 (0.44-0.80) z 0.74 (0.52-1.05)
Scar covering (yes vs. no) 0.97 (0.41-2.29) 1.13 (0.53-2.39) 0.87 (0.27-2.80) 0.84 (0.20-3.47)
Comorbidity (yes vs. no) 1.28 (0.96-1.71) 1.25 (0.97-1.62) 1.12 (0.74-1.67) 0.98 (0.62-1.56)
Therapy duration (>3 vs. 3) week 0.80 (0.67-0.94) z 0.37 (0.32-0.43) y 0.24 (0.20-0.29) y 0.42 (0.33-0.54) y
Therapy method
Intramuscular (glucantime 20 mg/kg
per day for 14 days)
Reference Reference Reference Reference
Intra lesional (glucantime; 20 mg/kg
per day for 10 to 20 days)
0.78 (0.64-0.91) z 0.36 (0.31-0.42) y 0.24 (0.20-0.29) y 0.42 (0.33-0.54) y
Cryotherapy with liquid nitrogen, once
per week for 6 weeks)
1.41 (0.96-2.08) 0.78 (0.54-1.12) 0.35 (0.18-0.66) z 0.59 (0.30-1.15)
Body region involved
Hand Reference Reference Reference Reference
Leg 0.75 (0.53-1.04) 0.97 (0.76-1.25) 0.86 (0.52-1.42) 0.99 (0.62-1.55)
Head (face, ear & neck) 4.21 (3.56-4.98) y 2 (1.70-2.35) y 6.61 (5.17-8.45) y 2.62 (2-3.44) y
Multi region involved 0.86 (0.66-1.14) 1.10 (0.90-1.36) 2.41 (1.76-3.29) y 1.65 (1.18-2.30) z
Duration of scar incidence (week) 1.02 (1.01-1.03) 1.05 (1.04-1.06) 1.05 (1.03-1.06) 1.04 (1.01-1.07)
Number of lesion 1.32 (1.27-1.37) y 1.10 (1.05-1.15) y 1.22 (1.16-1.29) y 1.18 (1.11-1.26) y
* Adjusted by age, sex and nationality.
y p-value 0.001; z p-value 0.01; § p-value 0.05.
E. Ayubi et al. / International Journal of Infectious Diseases 34 (2015) 61–6564in higher ages. Some of the studies that describe the epidemiologi-
cal context of CL in Iran have shown that most patients have
multiple lesions– mostly frequently in the upper extremities. The
peak infection rate is after the age of 20.3,4 Our ﬁndings support
these results, although in our study nearly 62% of patients had only
one lesion.
Furthermore, our results show that the occurrence of lesions on
the head (face, ear and neck) had the highest effect on adverse
post-treatment outcome. This might be due to the high frequency
of lesions on the face.Figure 3. Area under the curve (AUC) for assessing discriminant power of explanatory 
adverse post-treatment outcomes.A study reported that after the 2003 earthquake in the Bam
area, lesions on the face were more frequent than before the
natural disaster.8 A recent study found that a negative skin test was
a signiﬁcant prognostic determinant for post treatment relapse. It
has been identiﬁed that there was no signiﬁcant relationship
between the relapses and socio demographic (income or school-
ing) or clinical characteristics, such as number of lesions or
comorbidity,18 whereas the present study shows that with per unit
increase in the lesion number, the odds of relapse, treatment after
interruption, treatment failure, and clinical resistance is increasedvariables (infection outcome, clinical manifestation and treatment) to diagnosis of
E. Ayubi et al. / International Journal of Infectious Diseases 34 (2015) 61–65 65by 0.32, 0.10, 0.22, and 0.18, respectively; after adjustment for
confounding factors.
Our results showed that the complete duration of treatment
was a signiﬁcant protective factor for all adverse post-
treatment outcomes. Intra-lesional treatment seem to be
effective in CL caused by L.tropica in Iranian patients, compared
to cryotherapy. A study in another endemic area, i.e. Turkey,
indicated that intra lesional treatment was not effective and
90% of cases were cured by cryotherapy.19 One could
hypothesize that geographic area in which infection was
acquired is a determinant factor in treatment effectiveness.
Additionally, results from two Iranian studies showed that the
combination therapy (intra-lesional meglumine antimoniate
and cryotherapy) is highly effective for CL, caused by L.major
and L.tropica.20,21 A study of resistant parasites contributing to
treatment failure for ACL caused by L.tropica found that an
increasing proportion of patients with ACL are failing meglu-
mine antimoniate therapy other SbV-containing drug Pentos-
tam.22,23 In ROC analyses combination of all the outcome of
infection, clinical manifestation and treatment had different
power (low to moderate) to discriminate patients with and
without each adverse post-treatment outcomes. This means,
discrimination or diagnostic power, as reﬂected in the areas
under the ROC curves, was generally higher for treatment
failure compared to other outcomes.
The present study could be important because of the scarcity of
research on clinical outcomes after treatment of CL in Iran. Our
study has some limitations that should be considered. Some
relevant determinants were not considered, such as time lag
between the appearance of a CL lesion and the ﬁrst diagnosis, and
size of lesions. Other important factors were demographic and
socioeconomic variables such as occupation, because after the
2003 earthquake the huge workforces and laborers had rushed into
the Bam area. Unfortunately, data regarding the seasonal and
epidemiologic pattern of CL was not available. Because of
migration movement into the Bam area of Iranian and non
Iranians it is difﬁcult to deﬁne a plausible population and
generalize the results to other endemic regions.
To the best of our knowledge, there is a lack of published data on
the association between outcome of infection, clinical manifesta-
tion, treatment and adverse post-treatment outcomes in CL. After
the disastrous earthquake in the Bam area in 2003 the number of
adverse post-treatment outcomes increased. Reasons for this are
likely to be multifactorial. The results of this study imply that the
risk of outcome, e.g. relapse, depends on the body region involved.
Therefore, the occurrence of lesions on the head (face, ear and
neck) had the strongest effects. Completing treatment duration
could be an important protective factor to preclude adverse
outcomes. Finally, further longitudinal studies are required to
establish time order of predictor factors on adverse post-treatment
outcome.
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